Bcr-Abl is a “Molecular Switch” for the Decision for Growth and Differentiation in Hematopoietic Stem Cells

@article{Era2002BcrAblIA,
  title={Bcr-Abl is a “Molecular Switch” for the Decision for Growth and Differentiation in Hematopoietic Stem Cells},
  author={T. Era},
  journal={International Journal of Hematology},
  year={2002},
  volume={76},
  pages={35-43}
}
  • T. Era
  • Published 2002
  • Medicine, Biology
  • International Journal of Hematology
    • Chronic myeloid leukemia (CML) is a clonal disorder originating in the pluripotent hematopoietic stem cell (HSC), the hallmark of which is the constitutively activated p210-type of Bcr-Abl tyrosine kinase protein. Studies in recent years have helped us to understand the molecular processes involved in the initiation and progression of CML. Although a great amount of knowledge has been accumulated, the effect of Bcr-Abl on the HSC is still unclear. We have developed an in vitro system that… CONTINUE READING
    View on Springer
    ncbi.nlm.nih.gov
    12 Citations
    Highly Influencial Citations
    1
    Background Citations
    5
    Methods Citations
    1
    12 Citations
    Citation Type

    Citation Type

    c‐Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors
    • 11
    Two types of precursor cells in a multipotential hematopoietic cell line.
    • 33
    • PDF
    Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case report
    • 11
    Development of chronic myeloid leukaemia in patients treated with anti-VEGF therapies for clear cell renal cell cancer.
    • 13
    Differentiation status dependent function of FOG‐1
    • 22
    Targeting Human Cancer Stem Cells with Monoclonal Antibodies
    • 12
    • PDF
    Economic Burden of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia.
    • 9
    Targeting Cancer Stem Cells with Defined Compounds and Drugs
    • 20
    • Highly Influenced
    • PDF
    Tumour-initiating cells: challenges and opportunities for anticancer drug discovery
    • 741
    • PDF
    Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia.

    References

    SHOWING 1-10 OF 94 REFERENCES
    The role of Bcr-Abl in chronic myeloid leukemia and stem cell biology.
    • O. Witte
    • Biology, Medicine
    • Seminars in hematology
    • 2001
    • 27
    Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate.
    • T. Era, O. Witte
    • Biology, Medicine
    • Proceedings of the National Academy of Sciences of the United States of America
    • 2000
    • 130
    • PDF
    Consequences of BCR‐ABL Expression within the Hematopoietic Stem Cell in Chronic Myeloid Leukemia
    • 65
    BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia.
    • 134
    • PDF
    Genetic approaches to defining signaling by the CML-associated tyrosine kinase BCR-ABL.
    • 3
    Molecular Biology of Chronic Myeloid Leukemia
    • Y. Maru
    • Biology, Medicine
    • International journal of hematology
    • 2001
    • 41
    In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome.
    • 347
    • PDF
    BCR-ABL expression in different subpopulations of functionally characterized Ph+ CD34+ cells from patients with chronic myeloid leukemia.
    • 59
    • PDF
    Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
    • 449
    Bcr-Abl with an SH3 Deletion Retains the Ability To Induce a Myeloproliferative Disease in Mice, yet c-Abl Activated by an SH3 Deletion Induces Only Lymphoid Malignancy
    • 65
    • PDF